Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Petrichor Healthcare Capital Management

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 11
Average round size
The average size of a deal this fund participated in
Portfolio companies 7
Lead investments 2
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Biopharma
  • Pharmaceutical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Petrichor Healthcare Capital Management:
Typical Co-investors
Petrichor Healthcare Capital Management is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Petrichor Healthcare Capital Management:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Blue Dynamic -
Cellebrite HaMerkaz, Israel, Petah Tiqva
GLOBAL AGRINNO Hungary, Vas, Vasvár
H&M CO:LAB Stockholm, Stockholm County, Sweden
Hawkshead Capital -
Shanda Holdings -
SK Materials Seoul, Seoul-t'ukpyolsi, South Korea
Tennessee Community Ventures Nashville, Tennessee, United States
Value Invest Korea (VIK) Seoul, Seoul-t'ukpyolsi, South Korea

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Fennec Pharmaceuticals

Health Care
$25M11 Nov 2022 Durham, North Carolina, United States

Fennec Pharmaceuticals

Health Care
$20M26 Sep 2022 Durham, North Carolina, United States

Fennec Pharmaceuticals

Health Care
$45M01 Aug 2022 Durham, North Carolina, United States

Aurion Biotechnologies

$120M12 Apr 2022 Seattle, Washington, United States


Health Diagnostics
Medical Device
$15M23 Jun 2021 Germany, Bavaria, Germany

Isotopen Technologien München

Medical Device
$106M22 Apr 2021 Germany, Bavaria, Germany

Health Care
Medical Device
$7M29 Dec 2020 Irvine, California, United States

Health Care
Medical Device
$17M13 Jan 2020 Irvine, California, United States


Artificial Intelligence
Electronic Health Record (EHR)
Health Care
Information Technology
$15M10 Oct 2019 Marlborough, Massachusetts, United States
Leukocare Raises USD 17.5M in Financing

– Leukocare AG, a Martinsried/Munich, Germany and Milford, MA, USA-based biotechnology company specialized in the field of biopharmaceutical formulation development, closed a USD 17.5m (€14.6m) financing.
– The round was led by Petrichor Healthcare Capital Management with participation from existing shareholders.
– Proceeds will be used to accelerate Leukocare’s US expansion activities, bolster the company’s expertise in the fields of viral vector and vaccine formulation, as well as the emerging field of mRNA formulation, and to expand its suite of bioinformatics capabilities.

ITM Raises EUR 90 M (USD 109 M) to Accelerate Precision Oncology Pipeline and Support Ongoing Phase 3 Clinical Program

– ITM announced the successful close of a convertible loan financing totaling EUR 90 million (USD 109 million) led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors.
– The proceeds will support the expansion of ITM’s precision oncology pipeline as well as fund late-stage development and market access activities for lead candidate, n.c.a. 177Lu-Edotreotide, currently in a phase III trial in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
– Further details of the financing were not disclosed.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Petrichor Healthcare Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: